Setmelanotide is commonly sold or discussed for weight management, energy use, glucose control, and body composition research.
Also known as setmelanotide
Current picks · Nov 14, 2026
Up to three of the lowest effective prices per exact product among vendors that passed the trust floor, were in stock and checked within 72 hours, and have a COA on file for that product and strength tested within 12 months. Affiliate relationships never affect picks or their order.
No offer meets every pick rule today. The exact-product comparisons below still list every recorded price.
Same format. Same amount.
0 of 0 exact products have at least one pick. Vendor counts reflect the current price observations.
Vendor profiles and catalog information are still available below.
Historical market context
Historical market low and median per mg across recorded offers. These market summaries are separate from our exact-product comparisons.
History updated Sep 21, 2026. Vendor coverage, package sizes, product forms and promotions can vary over time. Use exact-product comparisons for current listed prices; historical market prices do not establish vendor trust.
| Date | Low /mg | Median /mg | Vendors | Offers |
|---|---|---|---|---|
| $6.00 | $6.00 | 1 | 1 | |
| $6.00 | $6.00 | 1 | 1 | |
| $6.00 | $6.00 | 1 | 1 | |
| $6.00 | $6.00 | 1 | 1 |
What it is
Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other earlier treatments for these patients included gastric bypass surgery. Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week. Imcivree was granted EMA orphan designation on November 19, 2018 and FDA approval on November 25, 2020. On May 4, 2023, it was approved by Health Canada. The listed molecular formula is C49H68N18O9S2. PepGrades separately preserves the catalog category because a chemical identity record does not establish a use, outcome, or product quality.
This label describes the available research record, not whether the compound is safe or effective for an individual.
Research context
5 registered studies were found under this name in the current review. Each study still needs to be checked for the exact compound identity, population, endpoints, and results.
Search indexed research for this compound ↗Market context
Setmelanotide is commonly sold or discussed for weight management, energy use, glucose control, and body composition research. That describes market demand, not proof that the compound is safe or effective.
Market demand and online discussion do not establish product quality, safety, or effectiveness.Vendor directory
Grades describe the vendor record overall, not a test of every product. Lowest prices are effective single-package prices across formats; open a comparison for the exact product.
No vendor has a current Setmelanotide offer on record.
1 tracked vendor lists Setmelanotide without a current offer: Polaris Peptides (Grade A-).
Sources and review
Last editorial review: Aug 30, 2026. Sources support the compound guide only and do not affect vendor grades.